HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.

Abstract
We have identified an H-2K(d)-binding peptide, HER2p780 (PYVSRLLGI), derived from murine HER2/neu (HER2), that can induce HER2-specific murine cytotoxic T lymphocytes (CTL). Weekly vaccination of BALB/c mice by syngeneic dendritic cells pulsed with HER2p780 peptide, entirely common to murine and human HER2, suppressed growth of pretransplanted HER2-expressing syngeneic tumors. A HER2-expressing human cancer cell line SKOV3 transfected with murine H-2K(d) cDNA could also be lysed by HER2p780-specific murine CTLs, indicating that human HER2-expressing cancer cells can process and present the cognate peptide in the context of H-2K(d). Since H-2K(d) and HLA-A2402 molecules have similar anchor motifs, the possibility of inducing HER2-specific CTL activity with HER2p780 in HLA-A2402 individuals was examined. CD8(+) CTL clones specific for HER2-expressing cancer cell lines were established from peripheral blood lymphocytes with HLA-A2402 by repeatedly sensitizing with peptide-pulsed autologous dendritic cells as well as peripheral blood mononuclear cells. Detailed analysis of their specificity revealed that the cytotoxicity of CTL clones is specific for the cognate peptide with HLA-A2402 restriction. The results suggest that HER2p780 is a unique peptide that may function as a tumor rejection antigen peptide in HLA-A2402 individuals, as it was directly proven here to function in a murine tumor system.
AuthorsY Ikuta, T Okugawa, R Furugen, Y Nagata, Y Takahashi, L Wang, H Ikeda, M Watanabe, S Imai, H Shiku
JournalInternational journal of cancer (Int J Cancer) Vol. 87 Issue 4 Pg. 553-8 (Aug 15 2000) ISSN: 0020-7136 [Print] United States
PMID10918197 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2000 Wiley-Liss, Inc.
Chemical References
  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • CD3 Complex
  • CD8 Antigens
  • Cancer Vaccines
  • Epitopes, T-Lymphocyte
  • HER2-neu-derived peptide (780-786)
  • HLA-A Antigens
  • HLA-A24 Antigen
  • Peptide Fragments
  • Receptor, ErbB-2
Topics
  • Animals
  • Antibodies, Monoclonal (immunology, pharmacology)
  • Antigen Presentation (immunology)
  • Antigens, Neoplasm (immunology)
  • CD3 Complex (immunology)
  • CD8 Antigens (immunology)
  • Cancer Vaccines (immunology)
  • Clone Cells
  • Dendritic Cells (immunology)
  • Epitopes, T-Lymphocyte (immunology)
  • HLA-A Antigens (immunology)
  • HLA-A24 Antigen
  • Humans
  • Lymphocyte Activation (immunology)
  • Mice
  • Neoplasm Transplantation
  • Peptide Fragments (immunology)
  • Receptor, ErbB-2 (immunology)
  • T-Lymphocytes, Cytotoxic (immunology)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: